Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Here, we report early treatment outcomes of gene therapy for early onset retinitis pigmentosa (RP) (Leber congenital amaurosis)associated with biallelic RPE65 mutation in a 30-year-old female patient. Initially, her visual acuity (VA) was 20/200, and her visu al field (VF) was severely constricted to the center in the left eye. Her electroretinography showed nearly extinct signals. Full-fieldstimulus threshold test (FST) revealed diminished dark-adapted light sensitivity. Voretigene neparvovec-rzyl (VN) is the first invivo viral gene therapy agent to be approved. At 3 months after subretinal injection of VN in the left eye, VA, VF, and FST showedsustained improvement. She did not exhibit any signs of adverse effects from the treatment. Gene therapy for RP proved to be aneffective and safe treatment in an advanced case of RPE65-associatied early onset RP.
Abstract
Here, we report early treatment outcomes of gene therapy for early onset retinitis pigmentosa (RP) (Leber congenital amaurosis)associated with biallelic RPE65 mutation in a 30-year-old female patient. Initially, her visual acuity (VA) was 20/200, and her visu al field (VF) was severely constricted to the center in the left eye. Her electroretinography showed nearly extinct signals. Full-fieldstimulus threshold test (FST) revealed diminished dark-adapted light sensitivity. Voretigene neparvovec-rzyl (VN) is the first invivo viral gene therapy agent to be approved. At 3 months after subretinal injection of VN in the left eye, VA, VF, and FST showedsustained improvement. She did not exhibit any signs of adverse effects from the treatment. Gene therapy for RP proved to be aneffective and safe treatment in an advanced case of RPE65-associatied early onset RP.
참고문헌 (18)
- Georgiou M, "Inherited retinal diseases : therapeutics, clinical trials and end points—A review", Clin Exp Ophthalmol, 49, pp.270~288 (2021)
- Travis GH, "Diseases caused by defects in the visual cycle : retinoids as potential therapeutic agents", Annu Rev Pharmacol Toxicol, 47, pp.469~512 (2007)
- Kang C, "Voretigene neparvovec : a review in RPE65 mutation-associated inherited retinal dystrophy", Mol Diagn Ther, 24, pp.487~495 (2020)
- Astuti GD, "Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark", Eur J Hum Genet, 24, pp.1071~1079 (2016)
- Ziccardi L, "Gene therapy in retinal dystrophies", Int J Mol Sci, 20, pp.5722~ (2019)
- Lopez-Rodriguez R, "RPE65-related retinal dystrophy : mutational and phenotypic spectrum in 45 affected patients", Exp Eye Res, 212, pp.108761~ (2021)
- Hull S, "Preserved visual function in retinal dystrophy due to hypomorphic RPE65 mutations", Br J Ophthalmol, 100, pp.1499~1505 (2016)
- Katagiri S, "Early onset flecked retinal dystrophy associated with new compound heterozygous RPE65 variants", Mol Vis, 24, pp.286~296 (2018)
- Kondo H, "A homozygosity-based search for mutations in patients with autosomal recessive retinitis pigmentosa, using microsatellite markers", Invest Ophthalmol Vis Sci, 45, pp.4433~4439 (2004)
- Maguire AM, "Clinical perspective : treating RPE65-associated retinal dystrophy", Mol Ther, 29, pp.442~463 (2021)
- Ciulla TA, "Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases : a model for ocular gene therapy development", Expert Opin Biol Ther, 20, pp.565~578 (2020)
- Gu SM, "Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy", Nat Genet, 17, pp.194~197 (1997)
- Chung DC, "The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene", Am J Ophthalmol, 199, pp.58~70 (2019)
- Russell S, "Efficacy and safety of voretigene neparvovec(AAV2-hRPE65v2)in patients with RPE65-mediated inherited retinal dystrophy : a randomised, controlled, open-label, phase 3 trial", Lancet, 390, pp.849~860 (2017)
- Maguire AM, "Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis : a phase 1 dose-escalation trial", Lancet, 374, pp.1597~1605 (2009)
- Weleber RG, "Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood–onset retinal dystrophy", Ophthalmology, 123, pp.1606~1620 (2016)
- Maguire AM, "Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease : phase 3 results at 3 and 4 years", Ophthalmology, 128, pp.1460~1468 (2021)
- Bennett J, "Five-year post-injection results of the phase 3 trial of voretigene neparvovec-rzyl in biallelic RPE65 mutation-associated inherited retinal disease", Investig Ophthalmol Vis Sci, 62, pp.3540~ (2021)